Oren, i think it depends on the partnership deal. If they get a good upfront payment along with milstones payments and if approved with very lucrative shared revenues deal, I would rather go for it. IMHO, this drug alone for this specific indication could be worth billions one day since there is no drug on themarket, easily can be sold as statins due to high prevelence in the population. Then, it all depends - with the money they get from the deal they may speed and expend their pipeline for many other indications/drugs.
News 
Market Data 
Discover 
